BioVaxys Technology (TSE:BIOV)
:BIOV
Top Page
No summary available
BioVaxys Technology (BIOV) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$1.75M
Dividend YieldN/A
Average Volume (3M)20.26K
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue GrowthN/A
EPS Growth25.09%
CountryCA
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding29,152,520
10 Day Avg. Volume17,758
30 Day Avg. Volume20,262
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-7.14
Price to Sales (P/S)0.00
P/FCF Ratio-4.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BioVaxys Technology Business Overview & Revenue Model
Company Description
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as ...
How the Company Makes Money
BioVaxys Technology generates revenue primarily through the development and commercialization of its vaccine candidates. The company aims to monetize its proprietary haptenized vaccines through licensing agreements, partnerships with pharmaceutica...
BioVaxys Technology Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Oct 2024 | Jan 2024 | Jan 2023 | Jan 2022 | Jan 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -3.99M | -3.95M | -7.69M | 0.00 | -6.42M | -1.09M |
| Net Income | -6.04M | -3.95M | -7.69M | -11.73M | -6.46M | -1.17M |
Balance Sheet | ||||||
| Total Assets | 1.39M | 1.30M | 113.48K | 865.56K | 8.50M | 10.46M |
| Cash, Cash Equivalents and Short-Term Investments | 4.08K | 211.81K | 977.00 | 141.90K | 593.12K | 2.42M |
| Total Debt | 133.72K | 68.08K | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 5.03M | 3.22M | 3.49M | 1.64M | 326.86K | 900.09K |
| Stockholders Equity | -3.64M | -1.92M | -3.37M | -773.53K | 8.18M | 9.56M |
Cash Flow | ||||||
| Free Cash Flow | -2.97M | -2.92M | -1.05M | -1.57M | -5.29M | -1.23M |
| Operating Cash Flow | -2.97M | -1.86M | -1.05M | -1.57M | -5.29M | -1.23M |
| Investing Cash Flow | 0.00 | -1.06M | 0.00 | 0.00 | 0.00 | 61.36K |
| Financing Cash Flow | 2.48M | 3.13M | 917.10K | 1.11M | 3.44M | 3.35M |
BioVaxys Technology Technical Analysis
Negative
0.06
Price Trends
0.12
Negative
0.18
Negative
0.23
Negative
Market Momentum
-0.02
Negative
28.01
Positive
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BIOV, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.12, and below the 200-day MA of 0.23, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 28.01 is Positive, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BIOV.
BioVaxys Technology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | C$1.75M | -1.60 | ― | ― | ― | 25.09% | |
46 Neutral | C$45.53M | -0.56 | -205.87% | ― | ― | 62.01% | |
45 Neutral | C$29.83M | -6.55 | ― | ― | ― | 72.92% | |
43 Neutral | C$589.63K | -6.34 | -10.30% | ― | ― | 46.32% | |
42 Neutral | C$43.30M | -4.40 | -103.51% | ― | ― | 54.74% | |
39 Underperform | C$38.15M | -12.93 | 72.34% | ― | ― | 10.49% |
* Healthcare Sector Average
TSE:BIOV
BioVaxys Technology
0.06
-0.44
-88.00%
TSE:ARCH
Arch Biopartners
0.57
-1.31
-69.68%
TSE:MDNA
Medicenna Therapeutics Corp
0.63
-0.27
-30.00%
TSE:BCT
BriaCell Therapeutics
6.28
-50.82
-89.00%
TSE:VXL
Vaxil Bio
0.15
-0.10
-40.80%
TSE:DTC
Defence Therapeutics
0.52
-0.38
-42.22%
BioVaxys Technology Corporate Events
Business Operations and StrategyExecutive/Board ChangesProduct-Related Announcements
BioVaxys Sharpens DPX Vaccine Strategy With New Leadership and Positive Breast Cancer Data
Positive
Jan 3, 2026
BioVaxys’ 2025 corporate review highlights the integration of the DPX platform into its operations and a strategic shift toward organic growth by expanding its early-stage pipeline, pursuing out-licensing opportunities, and re-engaging clini...
Business Operations and StrategyProduct-Related Announcements
BioVaxys Reports Promising Phase 1 Results for Breast Cancer Treatment MVP-S
Positive
Dec 17, 2025
BioVaxys Technology Corp. has reported positive phase 1 clinical study results for its innovative candidate MVP-S in combination with letrozole for treating HR+/HER2- stage II-III breast cancer. The trial demonstrated strong immune responses and s...
Business Operations and StrategyExecutive/Board Changes
BioVaxys Enhances Scientific Team with New Advisor
Positive
Dec 15, 2025
BioVaxys Technology Corp. has appointed Dr. Marianne Stanford as a Scientific Advisor, strengthening its scientific team with her extensive experience in vaccine development. Dr. Stanford’s expertise with the DPX platform, particularly in on...
Business Operations and StrategyPrivate Placements and Financing
BioVaxys Technology Completes Debt Settlement with Share Issuance
Neutral
Nov 25, 2025
BioVaxys Technology Corp. has completed a debt settlement transaction by issuing 1,792,387 common shares to settle an outstanding debt of $412,249. This move is part of the company’s financial strategy to manage its liabilities and strengthe...
Business Operations and StrategyPrivate Placements and Financing
BioVaxys Technology Secures $1.92 Million to Boost Immunotherapy Pipeline
Positive
Nov 19, 2025
BioVaxys Technology Corp. has successfully closed a non-brokered private placement financing, raising approximately $1.92 million through the issuance of over 11 million units. The funds will be utilized to enhance the company’s pipeline gro...
Business Operations and StrategyPrivate Placements and Financing
BioVaxys Announces Debt Settlement to Strengthen Financial Position
Positive
Nov 14, 2025
BioVaxys Technology Corp. has announced a debt settlement transaction with certain creditors, agreeing to issue up to 1,792,387 common shares at a deemed value of $0.23 per share to settle an outstanding debt of $412,249. This transaction, subject...
Business Operations and StrategyPrivate Placements and Financing
BioVaxys Extends Private Placement to Boost Immunotherapy Pipeline
Positive
Nov 12, 2025
BioVaxys Technology Corp. announced an extension of its non-brokered private placement financing to allow more investors to participate. The offering aims to raise up to $2,000,000 through the sale of units, each consisting of one common share and...
Business Operations and StrategyPrivate Placements and Financing
BioVaxys Upsizes Private Placement to Boost Immunotherapy Pipeline
Positive
Oct 30, 2025
BioVaxys Technology Corp. has announced an increase in its non-brokered private placement financing, aiming to raise up to $2 million. The proceeds will be used to expand its pipeline through licensing opportunities, research collaborations, and p...
Private Placements and Financing
BioVaxys Converts Debentures into Equity, Strengthening Financial Position
Positive
Oct 28, 2025
BioVaxys Technology Corp. announced the conversion of $125,000 in unsecured convertible debentures into common shares, resulting in the issuance of 665,465 shares at a conversion price of $0.19 per share. This conversion reflects investor confiden...
Business Operations and StrategyPrivate Placements and Financing
BioVaxys Converts Debentures to Strengthen Financial Position
Positive
Oct 22, 2025
BioVaxys Technology Corp. has announced the conversion of $160,670 in debentures into common shares, resulting in the issuance of 954,179 shares at a conversion price of $0.17 per share. This conversion reflects a strategic financial maneuver to m...
Business Operations and StrategyPrivate Placements and Financing
BioVaxys Converts Debentures and Grants Stock Options to Strengthen Market Position
Positive
Oct 21, 2025
BioVaxys Technology Corp. announced the conversion of $25,000 in unsecured convertible debentures into common shares by its CEO, James Passin, a transaction considered a related party transaction. Additionally, the company granted 550,000 stock op...
Business Operations and StrategyProduct-Related Announcements
BioVaxys Reports Positive Results for SpayVac Immunocontraceptive Vaccine
Positive
Oct 14, 2025
BioVaxys Technology Corp. and its licensee, SpayVac-for-Wildlife, Inc., have announced positive results from a study on their immunocontraceptive vaccine, SpayVac, which significantly reduced fertility in deer. The vaccine, which uses a patented l...
Business Operations and StrategyExecutive/Board Changes
BioVaxys Strengthens Board with Former Sanofi Executive
Positive
Oct 8, 2025
BioVaxys Technology Corp has appointed Dr. James Tartaglia, a former executive from Sanofi Vaccines, to its Board of Directors. Dr. Tartaglia’s extensive experience in vaccine RD is expected to bolster BioVaxys’s strategic focus on DPX...
Business Operations and StrategyPrivate Placements and Financing
BioVaxys Technology Corp. Launches Private Placement to Boost Immunotherapy Pipeline
Positive
Oct 7, 2025
BioVaxys Technology Corp. has announced a non-brokered private placement financing to raise between $1.2 million and $1.6 million through the sale of units consisting of common shares and warrants. The proceeds will be used to expand the company&#...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―